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The periaqueductal gray (PAG) is a brain region involved in nociception modulation, and an important relay center for the descending
nociceptive pathway through the rostral ventral lateral medulla. Given the dense expression of mu opioid receptors and the role of
dopamine in pain, the recently characterized dopamine neurons in the ventral PAG (vPAG)/dorsal raphe (DR) region are a potentially
critical site for the antinociceptive actions of opioids. The objectives of this study were to (1) evaluate synaptic modulation of the vPAG/
DR dopamine neurons by mu opioid receptors and to (2) dissect the anatomy and neurochemistry of these neurons, in order to assess the
downstream loci and functions of their activation. Using a mouse line that expresses eGFP under control of the tyrosine hydroxylase (TH)
promoter, we found that mu opioid receptor activation led to a decrease in inhibitory inputs onto the vPAG/DR dopamine neurons.
Furthermore, combining immunohistochemistry, optogenetics, electrophysiology, and fast-scan cyclic voltammetry in a TH-cre mouse line,
we demonstrated that these neurons also express the vesicular glutamate type 2 transporter and co-release dopamine and glutamate in a
major downstream projection structure—the bed nucleus of the stria terminalis. Finally, activation of TH-positive neurons in the vPAG/DR
using Gq designer receptors exclusively activated by designer drugs displayed a supraspinal, but not spinal, antinociceptive effect. These
results indicate that vPAG/DR dopamine neurons likely play a key role in opiate antinociception, potentially via the activation of
downstream structures through dopamine and glutamate release.
Neuropsychopharmacology (2016) 41, 2122–2132; doi:10.1038/npp.2016.12; published online 27 April 2016
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INTRODUCTION
Dopamine (DA) signaling has been demonstrated to play an
important role in the modulation of pain. Diseases impacted
by DA dysfunction, such as Parkinson’s disease, addiction,
and depression, are often comorbid with symptoms of
chronic pain (Weaver and Schnoll, 2002; Beiske et al, 2009;
Tykocki et al, 2013; Heimer et al, 2015; Hong et al, 2015).
Animal studies have implicated that DA modulates nocicep-
tion in various regions of the central nervous system,
including the basal ganglia, thalamus, insular cortex, anterior
cingulate cortex, and periaqueductal gray (PAG) (Wood,
2008; Jarcho et al, 2012). The PAG is of particular interest,
as it contains a relatively understudied population of DA
neurons and has been shown to play a role in opiate-
mediated antinociception, likely due to its dense expression
of mu opioid receptors (MORs). Moreover, antinociceptive
effects have been demonstrated via electrical stimulation of
the PAG (Mayer et al, 1971), local opioid (Akaike et al,
1978), cannabinoid (Finn et al, 2003), and GABA antagon-
ism within the PAG (Budai and Fields, 1998). While recent
studies have investigated the electrophysiological properties
of the DA neuron population in the ventral PAG/dorsal
raphe (vPAG/DR) (Dougalis et al, 2012; Li et al, 2013), little
is known regarding their modulation by opioid receptors.
Chemical lesion of PAG DA neurons attenuates opioid
induced antinociception, suggesting that this neuronal
population is a critical site of action (Flores et al, 2004).
Activation of opioid-class receptors in mice presynaptically
inhibits GABAergic transmission in the ventral tegmental
area (VTA), a DA-rich brain region, resulting in the
disinhibition of the DA neurons, and an increase in their
activity (Tan et al, 2010; Xie et al, 2012). Similar to the
VTA, MOR activation in the PAG reduces presynaptic
GABAergic neurotransmission in rats (Vaughan et al, 1997;
Hahm et al, 2011; Lecca et al, 2012). These studies suggest
opioid-mediated regulation of GABAergic tone modulates
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the activity of vPAG/DR DA neurons and antinociception.
There has been no direct evidence showing opioid-mediated
changes in inhibitory transmission in vPAG/DR DA
neurons, however, nor has there been any examination of
downstream synaptic or functional consequences of the
activation of vPAG/DR DA neurons.
In recent years, mounting evidence has suggested that
midbrain DA neurons in the VTA and substantia nigra can
co-release neurotransmitters such as GABA (Tritsch et al,
2012) or glutamate (Hnasko et al, 2010; Stuber et al, 2010;
Tecuapetla et al, 2010). It has yet to be determined if
activation of vPAG/DR DA neurons leads solely to the
release of DA or also to the co-release of other neuro-
transmitters. In this study, we used optogenetics in vPAG/
DR TH neurons to examine neurotransmitter release in the
bed nucleus of the stria terminalis (BNST), a projection
target of vPAG/DR. This allowed us to further clarify the role
of these neurons in downstream neural modulation. Finally,
we directly assessed the role of the vPAG/DR DA neurons in
regulation of pain-related behaviors using a chemogenetic
approach. Our results support the hypothesis that vPAG/DR
DA neurons are a critical cellular site of action of the
antinociceptive actions of opiates.
MATERIALS AND METHODS
Animals and Husbandry
Adult male tyrosine hydroxylase-eGFP (TH-eGFP) mice on a
Swiss Webster background, or TH-cre on a C57BL/6J
background (aged between 5 and 9 weeks, age matched for
behavioral assays), were obtained from the Mutant Mouse
Regional Resource Centers supported by NIH, bred and used
inhouse in accordance with an animal use protocol approved
by the University of North Carolina-Chapel Hill (IACUC).
GAD67 mice used for TH immunohistochemistry were
obtained from Dr Ben Philpot at the University of North
Carolina-Chapel Hill. Co-localization of vesicular glutamate
type 2 transporter (vGlut2) and TH utilized a mouse progeny
bred inhouse via a cross between a vGlut2-cre mouse
obtained from Dr Brad Lowell at the Beth Israel Deaconess
Medical Center at Harvard University Medical School and an
Ai3 mouse obtained from Dr William Snider at the
University of North Carolina-Chapel Hill. Mice were
group-housed under a 12–12 h light cycle, with lights on at
0700 hours daily. Mice were given ad libitum access to
rodent chow and water.
Stereotaxic Surgery
Mice were anesthetized with isoflurane and placed in a
stereotaxic frame (Kopf Instruments, Tujunga, CA). A
microinjection needle (32-gauge) was connected to a 1μl
Hamilton syringe mounted onto a digital micro-infusion
pump (KD Scientific, Holliston, MA). For electrophysiolo-
gical and optogenetic experiments, TH-cre mice were
injected with an AAV5-Eflα vector encoding DIO-Ch2
(H134R)-mCherry, unilaterally at an angle of 20° into the
vPAG/DR (250 nl, coordinates from Bregma AP − 4.5, ML
0.0, DV − 2.8). After a postsurgical period of 6 weeks, the
mice were killed and prepared for slice electrophysiology or
voltammetry. For behavioral experiments, TH-cre mice were
injected with an AAV8-Eflα vector encoding DIO-hM3Dq-
mCherry or the control fluorophore (AAV8-Eflα vector
encoding mCherry) at a 20° angle (500 nl, AP − 4.5, ML 0.0,
DV − 3.1). For vPAG/DR and VTA DA terminal
tracing experiments, TH-Cre mice were co-injected with
AAV5-EF1α-DIO-enhanced yellow fluorescent protein
(eYFP) in the vPAG/DR at a 20° angle (400 nl, AP − 3.7, ML
0.0, DV − 3.2) and AAV5-EF1α-DIO-mCherry in the VTA
(coordinate from Bregma: AP − 3.2, ML − 0.4, DV − 4.8).
Native fluorescence was imaged 4 weeks post-surgery.
Electrophysiology Brain Slice Preparation
Mice were decapitated under isoflurane anesthesia and their
brains were rapidly removed and placed in ice-cold sucrose
artificial cerebrospinal fluid (ACSF): (in mM) 194 sucrose, 20
NaCl, 4.4 KCl, 2 CaCl2, 1 MgCl2, 1.2 NaH2PO4, 10.0 glucose,
and 26.0 NaHCO3 saturated with 95% O2/5% CO2. Three
hundred micron slices were prepared using a Leica VT1200
vibratome (Wetzlar, Germany).
Slice Whole-Cell Electrophysiology
Brain slices containing the PAG were obtained and stored
at approximately 30 °C in a heated, oxygenated holding
chamber containing ACSF (in mmol/l) 124 NaCl, 4.4 KCl, 2
CaCl2, 1.2 MgSO4, 1 NaH2PO4, 10.0 glucose, and 26.0
sodium bicarbonate before being transferred to a submerged
recording chamber maintained at approximately 30 °C
(Warner Instruments, Hamden, Connecticut). Recording
electrodes (3–5MΩ) were pulled with a Flaming-Brown
Micropipette Puller (Sutter Instruments, Novato, CA) using
thin-walled borosilicate glass capillaries.
For mu opioid (MOR) inhibitory neurotransmission
experiments, recording electrodes were filled with
(in mmol/l) 130 CsCl, 10 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid, 2 QX-314, 10 EGTA, 2 ATP, 0.2 GTP,
pH 7.4, 290–295 mOsmol. Experiments were conducted
under voltage clamp configuration and cells were held at
− 70 mV. Inhibitory postsynaptic currents (IPSCs) were
pharmacologically isolated with 3 mmol/L kynurenic acid
to block α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic
acid and N-methyl-D-aspartate receptor-dependent postsy-
naptic currents. To isolate miniature IPSCs (mIPSCs),
tetrodotoxin (TTX, 0.5 μmol/l) was added to the perfusing
ACSF solutions described above. For evoked IPSC experi-
ments, currents were induced via twisted bipolar nichrome
wire placed lateral to the recording electrode. Electric output
was set to stimulate at 0.1 Hz paired pulses, between 5 and
50 V with a 100–150 μs duration.
Signals were acquired via a Multiclamp 700B amplifier
(Molecular Devices, Sunnyvale, California), digitized at
20 kHz, filtered at 3 kHz, and analyzed using Clampfit 10.2
software (Molecular Devices). Input resistance and access
resistance were continuously monitored during experiments.
Experiments in which changes in access resistance were
greater than 20% were not included in the data analysis.
Fast-Scan Cyclic Voltammetry
BNST slices were prepared from TH-cre(+/− )::ChR2 mice for
fast-scan cyclic voltammetry (FSCV) experiments as stated
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above for electrophysiology and perfused with ACSF. Carbon
fiber microelectrodes (CFMEs) were made as previously
described (Bath et al, 2000) and cut to 75 μm. For DA
detection, the CFME was positioned into the dorsal-lateral (dl)
BNST. A potential of − 0.4 V (vs Ag/AgCl) was applied to the
CFME and then rapidly ramped to 1.3 V (at 400 v/s) at a rate
of 10 Hz (Tar Heel CV software, Labview). Following 2 s
of background scans, the slices were stimulated with light
pulses from a blue LED (Thorlabs, 437 nm, 5ms pulse width,
1 mW) via a × 40 objective. Following detection, background
subtracted cyclic voltammograms (CVs) were analyzed using
HDCV software (Labview). Oxidative currents were detected
at the peak of oxidative potential corresponding to 0.6 V on
the CV.
Behavioral Experiments
Behavioral assays were conducted at least 3 weeks following
stereotaxic Gq designer receptors exclusively activated by
designer drug (DREADD) viral injection. Animals were aged
between 5 and 9 weeks at the time of stereotaxic surgery.
Littermate controls were age matched with Gq DREADD
animals to ensure that differences in behavioral phenotypes
were not the result of differences in age. On the day of
behavioral assays, 1 mg/kg CNO was administered to each
animal via intraperitoneal (i.p.) injection 45 min before its
respective trial to ensure Gq DREADD activation during
the assay.
Open Field
Each animal was placed in the center of an open field
chamber measuring 25 (L) × 25 (W) × 25 cm (H) for a 30-min
session. The chamber was enclosed in a fan-ventilated sound-
attenuation chamber with interior white LED illumination at
15 lux. Locomotor activity was measured by distance traveled
via the tracking software Noldus Ethovision 10.0.
Hot Plate and Tail Flick Assay
Both assays investigated the latency of response to
heat-induced pain. In the hot plate assay, each mouse was
gently placed into a cylindrical enclosure onto the heated
platform maintained at 52.5 °C. Each trial lasted 60 s to
minimize tissue damage. The first occurrence of hindpaw
licking, withdrawal, or jumping was recorded as response to
heat-induced pain (Espejo et al, 1994). In the tail flick assay,
each mouse was placed in a restraint tube and their tail
placed over the test apparatus approximately 2–3 cm from
the end. The latency to remove the tail from the apparatus
was measured. The intensity of the heated lamp stimulus was
set such that the baseline latency for tail removal was 3–5 s.
For each time point, two readings were taken 1 cm apart on
the tail and averaged together. Animals were tested prior to
CNO injection, 30 min following injection, and 1 h following
injection. Each trial lasted no more than 10 s to maximize
behavioral responses and minimize tissue damage. During
the first day of testing, animals were placed into the restraint
tube, without any habituation to the apparatus, and tested
immediately on the tail flick. To ensure that stress associated
with the restraint tube did not block any analgesic effects of
Gq DREADD activation, animals underwent two more
training sessions in which saline injections were adminis-
tered prior to animals being placed in the restraint tube and
analgesia was tested. The following day, animals underwent
test sessions with CNO injections prior to analgesia testing
(no differences to initial test, data not shown).
Immunohistochemistry
Mice were anesthetized with Avertin and perfused transcar-
dially with chilled 0.01M phosphate-buffered saline (PBS),
immediately followed by 4% paraformaldehyde PBS. Brains
were extracted and post-fixed in 4% paraformaldehyde for
24 h and then immersed in a 30% sucrose solution for 48 h,
both at 4 °C. Coronal sections 45 um in thickness were
collected using a Leica VT1000S vibratome (Leica Micro-
systems, Nussloch, Germany) and stored in a 50% glycerol
solution at − 20 °C until immunohistochemistry was
performed. Slices were rinsed four times for 5 min in chilled
PBS, followed by a 30-min incubation in 50% methanol,
a 5-min incubation in 3% hydrogen peroxide, three 10-min
PBS washes, a 30-min incubation in 0.5% Triton X-100 in
PBS solution, and a 10-min PBS wash. After a final 1-h
incubation in a blocking solution made of 0.1% Triton
X-100/10% Normal Donkey Serum in PBS, the tissue slices
were incubated overnight (~18 h) at room temperature with
their respective primary antibodies diluted in 0.1% Triton
X-100/10% Normal Donkey Serum in PBS blocking solution
(anti-TH (1 : 1000), Immunostar 22941-907001; anti-Green
Fluorescent Protein (1 : 500), Aves Laboratories, GFP-1020).
Slices were rinsed three times for 10min in chilled PBS before
incubating for 2 h in their respective secondary antibodies
diluted in PBS (Alexa Fluor 647 Donkey anti-Mouse (1 : 200),
TH; Alexa Fluor 488 Donkey anti-Chicken (1 : 200), GFP;
Jackson Immuno Research). Tissue was rinsed four times for
10min in chilled PBS, and mounted using Vecta-Shield
Mounting Medium (Vector Laboratories, Burlingame, CA,
H-1000) prior to image collection.
Statistics
Effects of drugs during electrophysiological recordings were
evaluated by comparing the magnitude of the dependent
measure (mIPSC frequency and amplitude) between the
baseline, wash-on (when drug had reached maximal effect at
10 min), and antogonist periods using one-way ANOVA
repeated measure test. The effects of antagonists/blockers on
the ability of drugs to modulate synaptic transmission were
compared using t-tests during the washout period. All values
given for drug effects throughout the article are presented as
mean ± SEM.
Drugs
Tetrodotoxin citrate (TTX, 500 nM) and kynurenic acid
(3 mM) were obtained from Abcam and dissolved in water.
Clozapine-n-oxide (CNO, 10uM for slice electrophysiology
bath application, 1 mg/kg for behavioral testing) stock was
dissolved in DMSO and diluted with ACSF (electrophysiol-
ogy) or saline (behavior) for use. [D-Ala2, NMe-Phe4,
Gly-ol5]-enkephalin (DAMGO) (300 nM) and D-Phe-Cys-
Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) (1 μM) were
purchased from Tocris and dissolved in water.
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RESULTS
Mu Opioid Receptor Modulation of vPAG/DR TH
Neurons
Activation of MORs has been shown to inhibit GABAergic
transmission onto VTA DA neurons in mice via a
presynaptic mechanism, thus increasing the activity of DA
neurons through disinhibition (Tan et al, 2010; Xie et al,
2012). In addition, MOR activation presynaptically reduces
GABAergic transmission onto PAG neurons in rats
(Vaughan et al, 1997; Hahm et al, 2011; Lecca et al, 2012).
Thus, we initially sought to investigate the effects of MOR
activation of GABAergic transmission onto vPAG/DR DA
neurons by recording from TH-eGFP reporter mice (Li et al,
2013). We first examined the ability of the MOR agonist,
DAMGO, to modulate electrically evoked IPSC (eIPSC) on
vPAG/DR DA neurons. In addition to changes in current
amplitude, we examined two parameters that are related to
presynaptic release properties: paired pulse ratio (PPR), and
coefficient of variation (CV). CV is defined as σ/μ, where σ is
the standard deviation of IPSC amplitude and μ is the mean
IPSC amplitude. At most central synapses, changes in PPR
are associated with modifications of the release probability,
while changes in CV are associated with alterations in the
release probability or the number of release sites. We found
that bath application of 300 nM DAMGO led to a robust
reduction of eIPSC amplitude (31.5± 8.1% of baseline, n= 7,
p= 0.0002; Figure 1a) that was partially reversed by
application of the MOR antagonist CTOP (62.4± 10.6% of
baseline, p= 0.01). While PPR during DAMGO application
(1.66± 0.4, n= 7, p= 0.44; Figure 1b) did not differ from that
of baseline (1.50± 0.3), CV analysis revealed a significant
change during DAMGO application (0.89± 0.1, n= 7,
p= 0.02; Figure 1b) compared with baseline (0.42± 0.05),
suggestive of a presynaptic site of action. change in the
number of release sites.
We next performed miniature IPSC recordings in the
presence of TTX (500 nM). Bath application of DAMGO
(300 nM) (representative traces; Figure 2a) for 10 min
significantly decreased mIPSC frequency (39.9± 5.88% of
baseline, n= 9, p= 0.004; Figure 2b and d) as well as
amplitude (85.88± 4.11% of baseline, n= 9, p= 0.0101;
Figure 2c and e) in the vPAG/DR TH neurons. In a subset
of these experiments, we explored the reversal of this
inhibition (Figure 2d and e) and found that DAMGO-
inhibition of mIPSC frequency was reversed by CTOP
(95.8± 12.0% of baseline, n= 7, F(1.366, 8.197)= 7.51,
p= 0.02) whereas amplitude was not (72.66± 6.5% of base-
line, F(1.096, 6.576)= 1.593, p= 0.25). This is consistent with
the partial reversal of DAMGO effects on evoked IPSC
shown earlier. To further confirm that the DAMGO effect
observed was mediated through MOR activation, we next
incubated the slices in CTOP for420 min before and during
DAMGO wash-on (n= 5). In the presence of the MOR
antagonist CTOP, DAMGO application failed to attenuate
mIPSC frequency (99.2± 2.9% of baseline; Figure 2h) or
amplitude (97.2± 5.4% of baseline; Figure 2i). Finally, we
examined the possibility of tonic MOR modulation on IPSC
inputs to the vPAG/DR TH neurons. The application of
CTOP alone did not affect mIPSC frequency (109.7± 4.8%
of baseline, figure not shown) or amplitude (96.4± 9.0% of
baseline), suggesting a lack of tonic GABA modulation by
MOR in vPAG/DR TH neurons. Additionally, these CTOP
antagonist data were collected as single 35-min recording
files (5 min baseline + 20 min CTOP wash-on + 10 min
DAMGO application). The matching timeframe to DAMGO
and CTOP reversal experiments provide support that the
observed effects of DAMGO on mIPSCs were not due to
rundown. Taken together, these results suggest that activa-
tion of MOR leads both to a reversible presynaptic inhibition
as well as a more persistent postsynaptic inhibition of GABA
function in vPAG/DR TH neurons.
Anatomy of vPAG/DR TH Neurons
We next explored the projections of vPAG/DR TH neurons
using VTA TH neurons as an anatomical reference. In a
TH-cre mouse line, we injected a cre-inducible virus
expressing eYFP into the vPAG/DR (Figure 3a) and one
expressing mCherry into the VTA. Serial sectioning of the
brain revealed several target regions of the vPAG/DR DA
neurons, of which the dBNST (Figure 3b) and the CeA
(Figure 3c) received the densest projections. Of particular
note, while the PAG projection to the rostral ventral lateral
medulla (RVLM) has been suggested to play a role in the
analgesic properties of opiates, we saw no evidence for a
dopaminergic projection there (data not shown). This is
Figure 1 Mu opioid receptor (MOR) activation reduced evoked inhibitory postsynaptic current (eIPSC) in the ventral periaqueductal gray/dorsal raphe
(vPAG/DR) dopamine neurons. (a) Application of MOR agonist [D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin (DAMGO) reduced eIPSC and was partially reversed
by the antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP). (b) DAMGO significantly increased the coefficient of variation (CV) but had no
effect on paired-pulse ratio (PPR). * denotes po0.05 in two-tailed paired Student’s t-test.
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consistent with a similar experiment (cre-inducible eYFP
injected in to the PAG/DR of TH-cre mice) performed at the
Allen Brain Institute (available online via the Allen Brain
Connectivity Map) which found a near identical result. To
more conclusively determine whether the vPAG/DR DA
neurons project to the RVLM, we injected retrograde beads
Figure 2 Mu opioid receptor (MOR) activation reduced mini inhibitory postsynaptic current (mIPSC) in the ventral periaqueductal gray/dorsal raphe
(vPAG/DR) dopamine neurons. (a) Representative baseline and post-drug traces demonstrating the effect of [D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin
(DAMGO) on mIPSC in the vPAG/DR dopamine neurons. (b, c) Cumulative probability distribution of frequency (b) and peak amplitude (c) before
application of DAMGO and followed by D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP). (d, e) Group effects (n= 10) demonstrating DAMGO
significantly reduced both mIPSC frequency (d) and amplitude (e). Time course demonstrating group (n = 7) DAMGO effects on frequency were reversed by
the MOR antagonist CTOP (f); however, effects on amplitude were not reversed (g). CTOP pretreatment blocked the DAMGO effects on mIPSC frequency
(h) and amplitude (i) (n = 7). * denotes po0.05 in two-tailed paired Student’s t-test.
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into the RVLM in a TH-eGFP mouse. We found neural cell
bodies with retrograde beads in the vPAG; however, they did
not co-localize with TH-expressing neurons (Figure 3d).
These results show that vPAG/DR DA neurons project to the
extended amygdala, but not to the RVLM.
Functional Neurochemistry of PAG/DR TH Neurons
Midbrain DA neurons in the VTA and substantia nigra can
co-release other neurotransmitters such as GABA (Tritsch
et al, 2012) or glutamate (Hnasko et al, 2010; Stuber et al,
2010; Tecuapetla et al, 2010), yet this has not been assessed
for PAG/DR TH neurons. We used immunohistochemistry
in mouse reporter lines to determine co-localization of TH
(Figure 4a) with markers of glutamate (vGlut2 reporter mice;
Figure 4b) and GABA neurons (glutamate acid decarbox-
ylase GAD67-GFP reporter mice; Figure 4d). Confocal
images indicate that vPAG/DR TH-expressing neurons
co-localize with vGlut2, but not GAD67 (Figure 4c and d).
Therefore, similar to DA neurons in the VTA, vPAG/DR DA
neurons may co-release glutamate in downstream target
regions.
We next investigated the possibility of DA/glutamate
co-release using cre-inducible channelrhodopsin (ChR2-
eYFP) in the vPAG/DR of TH-cre mice. We first verified
co-localization of ChR2-eYFP expression and TH-expressing
neurons in the vPAG/DR (Figure 5a). Using cell-attached
electrophysiology in the vPAG/DR ChR2-expressing cell
bodies, action potentials were successfully triggered in a
time-locked fashion with the presentation of blue LED at 1,
5, 10, and 20 Hz (Figure 5b), demonstrating our capability to
optically activate vPAG/DR TH neurons. Subsequently, we
recorded optically evoked currents from neurons in the
dBNST where vPAG/DR TH projections expressed ChR2.
For these recordings, a Cs-methanesulfonate-based internal
solution was used so that IPSCs were recorded at a holding
potential of +10 mV (Figure 5c) and EPSCs were recorded
at − 55 mV (Figure 5d) within the same dBNST neuron. Of
Figure 3 Ventral periaqueductal gray/dorsal raphe (vPAG/DR) tyrosine hydroxylase (TH) neurons project to bed nucleus of the stria terminalis (BNST) and
central nucleus of the amygdala (CeA), but not rostral ventral lateral medulla (RVLM). In a TH-cre mouse line, a cre-inducible enhanced yellow fluorescent
protein (eYFP) viral construct was injected into the vPAG/DR (a), and a cre-inducible mCherry virus into the VTA. eYFP-expressing vPAG/DR TH terminals
were observed in the BNST (b) and the CeA (c). In addition, when a retrograde bead injection was infused in the RVLM, neurons in the vPAG/DR that project
to RVLM did not co-localize with TH (d).
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the 19 dBNST neurons recorded, 13 had only light-evoked
glutamatergic currents, 4 had only light-evoked GABAergic
currents, and 2 had both light-evoked glutamatergic and
GABAergic currents. Upon inspecting the light stimulation
to current delay, we found a significantly shorter delay of the
glutamatergic currents (2.9 ± 0.16 ms; Figure 5e) relative to
the GABAergic currents (9.0± 1.5 ms. Student’s t-test
p= 0.007). The longer stimulation to current delay for
GABAergic currents, as wells as the infrequent occurrence
of light-evoked GABAergic currents, suggests that these
inhibitory currents could be due to polysynaptic activation of
GABA release, similar to what is seen in glutamatergic inputs
from the basolateral amygdala (Kim et al, 2013b).
Having established that vPAG/DR TH neurons could
release glutamate in the dBNST, we next utilized FSCV to
examine if activation of vPAG/DR TH terminals could elicit
DA release. In BNST slices from TH-cre mice expressing
ChR2-eYFP in vPAG/DR TH neurons, a CFME was placed
in the dBNST where fluorescent expression of ChR2-eYFP
was the strongest, and a blue LED was used to stimulate the
slice. We observed time-locked release of DA (DA) upon
optical stimulation of the slice. The current generated by DA
release positively scaled with pulse number (Figure 5f) and
exhibited both a CV (Figure 5g) and a color-plot (Figure 5h)
consistent with the oxidation and reduction of DA (n= 6).
While CVs for DA and norepinephrine are similar, the
enzyme necessary for norepinephrine synthesis, DA beta-
hydroxylase, is not present in the vPAG region (Flores et al,
2004), thus our signal is likely DA. Together, these results
suggest that in addition to co-expressing TH and vGlut2,
vPAG/DR TH neurons co-release DA and glutamate in
downstream target regions.
Causal Assessment of PAG/DR TH Neurons in
Pain-Related Behavior
We next examined the behavioral consequences of vPAG/DR
TH neuron activation using a chemogenetic approach. To
Figure 4 Ventral periaqueductal gray/dorsal raphe (vPAG/DR) tyrosine hydroxylase (TH)-positive neurons co-express vesicular glutamate type 2
transporter (vGlut2), but not markers for GABA transmission. (a–c) TH immunolabeling (A) in a vGlut2-Ai3 reporter mouse (b) demonstrated
co-localization of a subpopulation of vPAG/DR TH expression and vGlut2 expression (c). (d) TH immunolabeling in a GAD67-GFP reporter mouse,
illustrating vPAG/DR TH neurons and GABA neurons are distinct populations.
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selectively activate the vPAG/DR TH neurons, we used a
cre-inducible viral construct to express an excitatory
Gq-mediated DREADD in the vPAG/DR. Figure 6a shows
the co-localization of the Gq DREADD with TH staining,
confirming selective transduction in this TH-cre mouse line.
We also examined overlap with serotonin neurons by
co-staining with TPH2, a marker of 5HT neurons, and
found no evidence of co-localization (data not shown). To
functionally confirm the utility of the DREADD receptors in
acute slice electrophysiology, we bath applied the synthetic
DREADD ligand, clozapine-N-oxide (CNO, 10 μM), and
observed significant membrane potential depolarization
(4.8± 1.6 mV, n = 4; Figure 6b) in DREADD-expressing
neurons compared with the control mCherry-expressing
neurons. Having validated this approach ex vivo, we next
probed the role of vPAG/DR DA neurons in two different
nociception assays: the hot plate assay and the tail flick assay.
The tail flick response is a reflex response that can be elicited
after spinal cord transection (Franklin and Abbott, 1989);
however, the hot plate assay measures behavioral outputs
such as jumping, hindpaw withdrawal, and hindpaw licking
that requires supraspinal modulation, rather than reflexes. In
the hot plate assay, Gq DREADD activation via intraper-
itoneal (i.p.) 1 mg/kg CNO administration significantly
increased latency to paw withdrawal (46.1± 1.8s, n= 10 Gq
DREADD and 10 Control, p= 0.03; Figure 6c) in comparison
to controls (38.7± 2.7 s), suggesting an antinociceptive effect
upon vPAG/DR TH neuron activation. vPAG/DR TH
activation, however, showed no effect in the tail flick assay
(Figure 6d). In order to verify that the increase in hot plate
paw withdrawal latency was not due to changes in locomotor
function, we measured distance traveled in an open field
assay and observed no differences in either the Gq DREADD
or control conditions (Figure 6e).
DISCUSSION
The results of this study provide evidence that MOR
activation inhibits GABAergic inputs onto vPAG/DR DA
neurons through both presynaptic and postsynatpic
mechanisms of action. Moreover, we found that activation
of vPAG/DR TH neurons can modulate a subclass of
pain-related behaviors, and that these neurons overlap with
a population of vGlut2 neurons to functionally release both
DA and glutamate in the BNST. Together, this suggests that
the DA neurons of the vPAG/DR are a critical neuronal
substrate for opiate-induced regulation of pain.
MOR Actions on vPAG/DR DA Neurons
Similar to studies on DA neurons in the VTA, we found that
ex vivo bath application of the MOR ligand DAMGO
significantly reduced evoked IPSCs as well as mIPSC
frequency and amplitude. In the evoked experiments, the
inhibiting effect of DAMGO was partially reversible by
application of the antagonist, while in the miniature
experiments, the effect of DAMGO on frequency was
completely reversed by the antagonist, but not the amplitude.
Overall, this is consistent with a model in which there is
Figure 5 Ventral periaqueductal gray/dorsal raphe (vPAG/DR) tyrosine hydroxylase (TH) neurons release dopamine and glutamate in the bed nucleus of
the stria terminalis (BNST). In a TH-cre mouse line, a cre-inducible channelrhodopsin viral construct was injected into the vPAG/DR. (a) Confocal image
demonstrates the high-degree of colocalization of channelrhodopsin enhanced yellow fluorescent protein (green), and TH staining mCherry (red) in the
injection site. (b) In the vPAG/DR, blue light presentation induced light-evoked action potentials in TH cell bodies expressing channelrhodopsin. In the BNST,
channelrhodopsin-mediated light activation of vPAG/DR TH terminals evoked both GABAergic (c) and glutamatergic (d) currents in the post-synaptic BNST
neurons, with GABAergic current displaying a significantly increased latency to current onset (e). (f) Using fast-scan cyclic voltammetry (FSCV), dopamine
release from the vPAG/DR TH terminals was detected in the BNST at different optogenetic stimulation parameters. (g) Cyclic voltammogram of dopamine
release. (h) FSCV color plot representing dopamine release.
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acute suppression of GABA release following activation of
MOR, similar to other studies (Johnson and North, 1992;
Lupica, 1995; Bergevin et al, 2002). However, our results also
suggest a potential persistent postsynaptic inhibition, which
to date has not been reported. This is particularly intriguing
in light of recent evidence for postsynaptic MOR function in
VTA DA neurons (Margolis et al, 2014). These results
suggest that MOR activation reduces inhibitory input and
therefore potentially disinhibits vPAG/DR DA neurons in
order to modulate downstream circuits.
Functional Neuroanatomy of vPAG/DR DA Neurons
We used a viral-based tracing approach to examine the
outputs of vPAG/DR DA neurons. Consistent with several
other studies, we found that these neurons project densely to
the extended amygdala; in particular, the BNST and the CeA
(Rizvi et al, 1991; Vianna and Brandao, 2003; Kim et al,
2013a). Interestingly, while VTA DA neurons have similar
outputs, there appeared to be distinct patterns of innerva-
tions when we directly compared the projections. The vPAG/
DR DA neurons appeared to strongly innervate the oval
nucleus of the BNST, whereas VTA DA neurons target a
portion of the BNST lateral to the oval nucleus. These
distinct projections suggest that activation of these inputs
may lead to recruitment of different microcircuits, an
important possibility, given the heterogeneity of the BNST
(Kim et al, 2013b). Interestingly, we found no evidence for
innervation of the RVLM by vPAG/DR DA neurons using
either viral-based mapping or classic retrograde labeling.
Given that local DA signaling in the PAG/DR can modulate
pain-related behaviors, this suggests that vPAG/DR DA
neurons may serve to locally modulate RVLM-projecting
neurons in addition to modulation of distinct target regions,
which may be important for coordinating the emotional and
visceral aspects of pain.
Following the examination of projection targets, we used
immunohistochemistry in well-characterized reporter mice
to demonstrate that vPAG/DR DA neurons co-express
vesicular glutamate transporter 2 (vGlut2), but are not
GABAergic. Using a ChR2eYFP-based mapping approach,
we then functionally assessed neurotransmitter release in the
BNST, a region that receives dense innervation of vPAG/DR
DA neurons. We found via cyclic voltammetry, for the first
time, that stimulation of vPAG/DR DA neurons could
release both DA and glutamate in the BNST. Interestingly,
the vast majority of cells recorded received glutamatergic
input (68%) upon optical stimulation while few cells (21%)
received inhibitory or mixed (11%) excitatory/inhibitory
input. This was surprising given our immunohistochemistry
data showing that vPAG/DR DA neurons co-express vGlut2
but not GAD67. The light-evoked GABAergic currents,
however, exhibit a significantly longer stimulation-to-current
onset delay when compared with the glutamatergic currents.
These GABAergic currents are likely due to a local
polysynaptic microcircuit engaged by DA or glutamate
release from the vPAG/DR DA rgic projections, a model
consistent with results demonstrating that DA can depolarize
a discrete subpopulation of neurons in the BNST (Kash et al,
2008; Silberman and Winder, 2013). However, it is important
to recognize one potential limitation of our findings
regarding co-release of DA and glutamate. While our
Figure 6 Activation of Gq signaling in ventral periaqueductal gray/dorsal raphe (vPAG/DR) tyrosine hydroxylase (TH) neurons reduces response in hotplate
but not tail flick or locomotor activity. Gq designer receptors exclusively activated by designer drug (DREADD) was virally expressed in vPAG/DR DA neurons
in a TH-cre mouse. (a) Confocal images demonstrated colocalization of Gq DREADD-mCherry, and TH staining GFP in the injection site. (b) In slice
electrophysiology, bath application of CNO (10 μM) depolarized vPAG/DR TH neurons. Chemogenetic activation of vPAG/DR TH neurons significantly
increased latency to paw withdrawal in hotplate assay (c). However, no effects were observed in tail flick latency (d) or locomotion (e). * denotes po0.05 in
two-tailed paired Student’s t-test.
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staining revealed that ChR2-eYFP was expressed predomi-
nantly in TH-expressing neurons, there were a small number
of neurons that did not appear to express detectable levels of
TH protein. It is possible that some of these neurons express
cre under the TH promoter but do not express TH protein,
resulting in non-dopaminergic glutamate neurons expressing
ChR2-eYFP in our preparation, and resulting in glutamate
release upon light activation. This possibility, however, is
mitigated by our staining demonstrating co-expression of
TH in vGlut2-positive neurons.
Our results demonstrate the release of both glutamate and
DA in the BNST from vPAG DA neurons. In addition to the
substantial modulatory role of the vPAG/DR in nociception,
the BNST also demonstrates pain-dependent neural re-
sponses in rats (Morano et al, 2008). Lesion of the BNST
blocks pain-induced conditioned place aversion (Deyama
et al, 2007), and prevents shock-induced sensitization of the
vocalization response to heat (Crown et al, 2000). Further-
more, the BNST modulates the emotional aspect of pain
(Minami and Ide, 2015). These data, in conjunction with our
data, suggest that input from the vPAG/DR DA neurons
modulate BNST functions pertaining to pain.
Chemogenetic Activation of vPAG/DR Neurons Revealed
a Role in Pain-Related Behaviors
Lastly, via chemogenetic techniques using the excitatory Gq
DREADDs, we probed the functional consequences of
selective vPAG/DR DA neuron activation in two different
nociception assays: the hot plate and the tail flick tests to
assess changes in supraspinal and reflex response, respec-
tively. Previous studies have suggested that vPAG/DR
activation mediates antinociception in a supraspinal manner,
consistent with our findings that activation of vPAG/DR DA
neurons increased latency to hindpaw withdrawal in the hot
plate assay, but did not alter responses in the tail flick assay
(Flores et al, 2004). It is unlikely that this difference was due
to altered locomotion following activation of these neurons,
as we detected no significant difference in movement
between Gq DREADD activation of vPAG/DR DA neurons
compared with mCherry controls.
CONCLUSION
Here we provide the first demonstration that the MOR
inhibits GABA function in vPAG/DR DA neurons, primarily
through inhibition of release. Moreover, we demonstrate
that these neurons densely innervate the extended amygdala
(specifically the BNST) where they can release both
glutamate and DA. Finally, we demonstrate that chemoge-
netic activation of vPAG/DR DA neurons can alter pain-
related behaviors. Taken together, this study provides a
mechanistic understanding of how MOR activation within
the vPAG/DR can alter nociception, and provides a discrete
cellular target for development of novel pain medications.
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